"alpha-Synuclein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synuclein that is a major component of LEWY BODIES that plays a role in neurodegeneration and neuroprotection.
| Descriptor ID |
D051844
|
| MeSH Number(s) |
D12.776.631.860.500 D12.776.637.500
|
| Concept/Terms |
alpha-Synuclein- alpha-Synuclein
- alpha Synuclein
- Non-AB Component of AD Amyloid Protein
- Non AB Component of AD Amyloid Protein
|
Below are MeSH descriptors whose meaning is more general than "alpha-Synuclein".
Below are MeSH descriptors whose meaning is more specific than "alpha-Synuclein".
This graph shows the total number of publications written about "alpha-Synuclein" by people in this website by year, and whether "alpha-Synuclein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 4 | 6 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 3 | 3 | 6 |
| 2011 | 1 | 2 | 3 |
| 2012 | 4 | 0 | 4 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 7 | 0 | 7 |
| 2019 | 4 | 3 | 7 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 2 | 5 |
| 2022 | 2 | 1 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "alpha-Synuclein" by people in Profiles.
-
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec; 30(12):3669-3675.
-
Olfactory deficit and gastrointestinal dysfunction precede motor abnormalities in alpha-Synuclein G51D knock-in mice. Proc Natl Acad Sci U S A. 2024 Sep 24; 121(39):e2406479121.
-
Parkinson's disease variant detection and disclosure: PD GENEration, a North American study. Brain. 2024 Aug 01; 147(8):2668-2679.
-
Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of a-synuclein inclusions. Neuron. 2024 Sep 04; 112(17):2886-2909.e16.
-
Functional screening of lysosomal storage disorder genes identifies modifiers of alpha-synuclein neurotoxicity. PLoS Genet. 2023 05; 19(5):e1010760.
-
Microglia and astrocyte activation is region-dependent in the a-synuclein mouse model of Parkinson's disease. Glia. 2023 Mar; 71(3):571-587.
-
Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping. Cerebellum. 2024 Feb; 23(1):31-51.
-
Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 08 04; 387(5):421-432.
-
Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies. CNS Drugs. 2022 04; 36(4):327-343.
-
1-Indanone and 1,3-indandione Derivatives as Ligands for Misfolded a-Synuclein Aggregates. ChemMedChem. 2022 01 19; 17(2):e202100611.